Navigation Links
More Evidence for Oxaliplatin as Colon Cancer Chemotherapy
Date:1/20/2012

FRIDAY, Jan. 20 (HealthDay News) -- Adding oxaliplatin to a standard chemotherapy regimen boosts survival rates for patients with advanced colon cancer, according to a new study that bolsters previous research on the drug by looking at a broader group of patients.

"Physicians and patients should be reassured from our findings that oxaliplatin is associated with marginally but consistently superior survival for patients diagnosed before age 75 years in community settings," the study authors said in a news release.

In past studies, oxaliplatin, as an adjuvant to the established treatment of 5-fluorouracil (5-FU), improved survival by up to 23 percent. But the new study looked at a different group of colon cancer patients, who were older, sicker, more racially diverse and had never participated in a controlled clinical study.

The study, led by Dr. Hanna Sanoff, an assistant professor of medicine, hematology and oncology at the University of Virginia School of Medicine, appears in the Jan. 20 issue of the Journal of the National Cancer Institute.

Colon cancer is one of the world's deadliest diseases, with more than 100,000 Americans diagnosed last year, the researchers noted. Of these, roughly a third had an advanced -- stage 3 -- cancer, for which surgery is the principal treatment.

Surgery alone produces disease-free survival rates of between 15 percent and 50 percent five years following treatment, according to study background information. To improve their chances, patients often also undergo post-surgical chemotherapy.

Up until 2004, the drug 5-FU -- given in combination with leucovorin, which boosts its effects -- was the chemotherapy of choice for colon cancer, sparking a 26 percent drop in death rates compared to patients undergoing surgery alone.

But in 2004, several U.S. National Cancer Institute studies indicated that by adding oxaliplatin to the 5-FU mix, patients could see survival rates rise by yet another 23 percent.

The one caveat: Only a tiny slice of cancer patients (less than 2 percent) participated in those clinical trials, and those tended to be younger, healthier and less diverse than the larger general population of colon cancer patients.

To determine whether oxaliplatin would show a similar benefit among a "real-world" population of patients, the authors sifted through five cancer registries containing survival information on more than 4,000 people with stage 3 colon cancer. All were younger than 75, and all had begun chemotherapy -- either a standard regimen or in combination with oxaliplatin -- within four months of having surgery between 2004 and 2009.

Researchers compared their survival rates with those of nearly 8,300 patients who had participated in one of five different clinical trials using oxaliplatin.

The addition of oxaliplatin to standard chemotherapy protocols was found to be just as effective in prolonging survival among the community-based set of patients -- including the elderly, minorities and those with additional complicating health issues -- who were not enrolled in studies.

For her part, Dr. Felice Schnoll-Sussman, a gastroenterologist at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City, said the finding "goes along with what we've previously known."

"So, it's not surprising," she said. "But, certainly this is positive. The analysis doesn't focus on some of the most common adverse reactions seen with this combination. But in terms of survival, it certainly supports our previously held belief that oxaliplatin increases survival and lowers the chance of cancer returning in some of those stage 3 post-surgery patients."

More information

For more on colon cancer, visit the U.S. National Library of Medicine.

Alan Mozes

SOURCES: Felice Schnoll-Sussman, M.D., gastroenterologist, New York-Presbyterian Hospital/Weill Cornell Medical Center, New York City; Journal of the National Cancer Institute, news release, Jan. 19, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Herbal Medicines for Arthritis Not Backed by Evidence
2. Study shows no evidence of a mortality benefit to PSA screening
3. New evidence that bacteria in large intestine have a role in obesity
4. More Evidence Links Specific Genes to ADHD
5. More Evidence That HPV Vaccine Shields Against Cervical Cancer
6. Evidence base for exercise programs for older people still in the balance
7. Weak evidence to support exercise referrals
8. Little Evidence of Heart Risks From ADHD Meds
9. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
10. Clinical trial shows first evidence that anal cancer is preventable
11. Researchers have found evidence for the existence of a hypnotic state
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More Evidence for Oxaliplatin as Colon Cancer Chemotherapy
(Date:5/2/2016)... ... , ... East Los Angeles dentist , Dr. Ramin Assili, is now ... receive any dental extraction treatment for $40 off the regular price. This promotion cannot ... lower price, patients can more easily afford extractions to eliminate teeth that are damaged ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Further establishing ... to announce that the new WHIMZEES Variety Value Boxes were selected from over 1,000 ... Product Showcase Award. , WHIMZEES natural dental chews for dogs are a favorite ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... itself around major organs, such as the kidneys, liver and pancreas. If not ... M.D ., a board-certified physician in Internal Medicine, Medical Oncology and Palliative Care, ...
(Date:5/2/2016)... ... 2016 , ... According to an American Psychological Association article, the ... before the age of 18. Of those who survive, many still face effects as ... , In her new book, Lyah! Lyah! Pants on Fyah!, she shares stories from ...
(Date:5/2/2016)... ... 2016 , ... TeleMedCo™, a new company developing real time ... the rapid diagnosis, triage and admission of patients leveraging IBM Watson’s software and ... for the first time at GENBAND’s Perspectives16 conference. , TeleMedCo selected GENBAND’s ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... 29, 2016 ReportsnReports.com adds ... market research report that provides an overview of ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
(Date:4/28/2016)... April 28, 2016   Click here for ... Inc. (NYSE: DPLO), the nation,s largest independent specialty ... definitive agreement to acquire Valley Campus Pharmacy, Inc., ... a leading specialty pharmacy that provides individualized patient ... . In 2015, TNH generated approximately $400 ...
(Date:4/28/2016)... 2016  The blood testing market in ... Kalorama Information and The Freedonia Group in a recent ... testing.  The healthcare research firm said that ... collection stations and in improving testing at the provincial ... Blood Testing Market in China , ...
Breaking Medicine Technology: